1228 results about "Nephrosis" patented technology

The invention relates to the technical field of medical health big data analysis, in particular to a diabetic nephropathy risk identification method and system based on big data analysis, and the method comprises the following steps: screening key index features of risk patients through big data analysis based on health risk data of diabetic nephropathy patients; association of key indexes of the risk patients is analyzed, risk index interaction features are extracted, risk feature constraint conditions are determined, virtual sample parameters are identified through multi-dimensional data association, and a virtual sample set of the risk patients is established. According to the method, interaction characteristic values are extracted by analyzing key indexes of risk patients, high-risk index association is accurately captured, coverage and balance are enhanced based on multi-dimensional data association, non-stationary influence is solved by combining time sequence key change rate and shear point identification, and accurate matching is realized by analyzing offset rate and change trend. And the overall risk level is quantitatively evaluated by integrating interval data weighting, so that the risk identification comprehensiveness and the result reliability are improved.

The invention discloses a peritoneal dialysis anti-blocking high-circulation nursing device for pediatric nephropathy patients, and belongs to the technical field of medical nursing. Comprising the following modules: a multi-mode sensing module for collecting pressure, flow velocity, turbidity, vibration spectrum and temperature data in a catheter in real time; the signal optimization processing module highlights weak features of potential blockage and improves data quality; the feature fusion analysis module is used for comprehensively evaluating the state of the catheter; the AI prediction analysis module is used for predicting the occurrence probability, the position and the possible time window of blockage; the risk early warning and intervention module is used for sending out graded early warning signals according to the prediction result and generating personalized anti-blocking intervention suggestions; the micro-fluidic execution module inhibits formation of initial sediments through a micro-pulse technology and dynamic fluid mechanics adjustment, and effectively reduces the risk of blockage; and the remote medical support module provides visual data visualization and intervention suggestions, supports remote monitoring and emergency intervention, and is seamlessly integrated with a hospital system while ensuring data security.

The invention relates to the field of medical information processing and traditional Chinese medicine curative effect evaluation, in particular to a diabetic nephropathy traditional Chinese medicine curative effect evaluation method based on patient report outcome. The method comprises the following steps: searching related symptoms and clinical characterization data of diabetic nephropathy through a medical database, extracting target entries, performing language standardization processing, constructing an initial candidate entry set, calculating the occurrence frequency of each symptom entry, and screening entries meeting a set threshold value to form an entry set; carrying out dimension division on the entry set according to feature attributes to form a preliminary dimension structure set; forming a screening result set through preset logic screening conditions; and carrying out weighted regression fusion on the comprehensive curative effect score and clinical detection data, and outputting a patient curative effect index. In an item weight determination process, dynamic balance between subjective experience and objective statistical information is realized through a mixed weighting model, and the defects of strong subjectivity of expert scoring and large result fluctuation in a traditional method are overcome.

Disclosed are naphthyl compounds comprising either a ureido piperidine-1 -carboxamide or a ureido piperidine-1 -carboxylate moiety, compositions thereof, and methods of use thereof, for treating or preventing a disease or disorder associated with abnormal levels of amino acids by modulation of SLC6A19 transport, such as phenylketonuria, hyperphenylalaninemia, diabetes and chronic kidney disease.

A class of compounds and the use thereof in a drug. Specifically, the present invention relates to a class of new compounds, a pharmaceutical composition containing the compounds, a method for preparing the compounds, and the use of the compounds or the pharmaceutical composition in the preparation of a drug for treating GLP-1 receptor agonist-mediated diseases and / or disorders, particularly the use in the preparation of a drug for treating diabetes, non-alcoholic fatty liver disease, obesity, myocardial infarction, heart failure, diabetic nephropathy, Parkinson's disease and Alzheimer's disease.

The invention discloses a diabetic nephropathy risk assessment and prediction system based on platelet indexes, and particularly relates to the technical field of disease risk prediction, which comprises a platelet index acquisition module, a drug use data acquisition module, a drug intervention assessment module, an index correction module, a clustering analysis module and a diabetic nephropathy risk assessment module, the method comprises the following steps: acquiring platelet related detection indexes and historical medication data of a patient, calculating a drug intervention influence index and generating a correction factor, realizing platelet index reverse reduction correction by adopting a convolutional neural network model, determining a similar group in combination with clustering analysis, and dynamically evaluating the risk of diabetic nephropathy based on the average morbidity of the group. Personalized accurate prediction is realized; the platelet index correction accuracy is improved, individualized drug intervention elimination is achieved, the similar population clustering analysis precision is enhanced, diabetic nephropathy risk prediction is dynamically adjusted in combination with comprehensive scores, and the early screening and individualized intervention effects are improved.

The present invention provides a method for increasing glycemic control in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt thereof. The present invention provides a method for improving weight management in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt thereof. Further providing a method for treating a condition selected from atherosclerosis, chronic kidney disease, NAFLD, and NASH. Further provided is a method to prevent or induce remission of diabetes comprising administration of tirzepatide, or a pharmaceutically acceptable salt thereof. Further provided is a dosing regimen for increasing glycemic control, improving weight management, and / or treating dyslipidemia.

The invention relates to the technical field of medical health management, in particular to a chronic kidney disease and diabetes collaborative nutrition monitoring and early warning method and system.The method comprises the steps that multi-dimensional physiological indexes, nutrition intake and sleep data of a patient are obtained, and a dynamically-coupled metabolic state topological space is constructed; based on the space, constructing a dual-disease metabolism coupling matrix, analyzing stability characteristics of a metabolism state trajectory, identifying stable and unstable attractors, and calculating a multi-dimensional risk score; a sleep-metabolism synchronism risk prediction model is introduced, and a personalized early warning threshold value is dynamically adjusted; when the risk score exceeds a threshold value, early warning is triggered, and intervention suggestions are generated, the interactive influence of protein metabolism and glycometabolism is quantitatively described from the metabolic mechanism level, and the contradiction of chronic kidney disease and diabetic patients in nutrition management is solved; limitation of a static threshold is broken through, and dynamic risk assessment is realized; sleep factors are creatively integrated, and a new way for improving the metabolic state is provided.

The invention provides a hypertensive nephropathy prediction method based on multi-model fusion screening characteristics. An important feature set influencing the occurrence of hypertensive nephropathy is screened based on a multi-model fusion method, and a hypertensive nephropathy prediction model based on multi-model fusion is established by using the feature set. Early screening work for hypertension people is realized, so that the risk of hypertensive nephropathy can be found as early as possible, timely treatment is realized, and the prognosis of patients is improved.

The invention provides a multi-modal kidney pathological picture processing method and device, electronic equipment and a medium. The method comprises the following steps: acquiring an immunofluorescence picture included in a to-be-processed multi-modal kidney pathological picture and a PAS staining pathological picture corresponding to the immunofluorescence picture; inputting the immunofluorescence pictures into a pre-trained first network model to perform nephropathy type classification to obtain nephropathy types; judging whether the nephropathy type output by a pre-trained first network model belongs to a preset nephropathy type or not; inputting a PAS staining pathological picture corresponding to the immunofluorescence picture into a pre-trained second network model for pathological structure identification when the immunofluorescence picture belongs to the preset nephropathy type, and outputting a label for the identified pathological structure; and adding an Oxford typing label to the to-be-processed multi-modal kidney pathological picture based on a label and a pathological structure output by a pre-trained second network model. According to the scheme, the nephropathy type can be automatically distinguished, the Oxford typing label is added, the processing speed is high, and the accuracy rate is high.

The invention discloses a method for constructing a differential diagnosis model for lupus nephritis and membranous nephropathy, and belongs to the technical field of intelligent medical treatment. The modeling method comprises the following steps: S1, respectively collecting flow cytometry detection data of lupus nephritis patients and healthy control personnel; s2, performing data cleaning and conversion on the flow cytometry detection data, and converting non-numerical features into digits; carrying out implication on the missing value by adopting a k nearest neighbor algorithm from an implication packet; s3, random sampling is carried out on the cleaned and converted data set, and samples are divided into a training set and a verification set according to the proportion of 7: 3; s4, dividing a training subset and a test set from the training set, and iteratively selecting the types of cells incorporated into the constructed model as pDC, CD4T, effector CD4T, Th2, CD8T, CD38 + HLA-DR + CD8T, and CD38 + PD-1 + CD8T by adopting an RFE method, wherein the types of the cells incorporated into the constructed model are pDC, CD4T, effector CD4T, Th2, CD8T, CD38 + HLA-DR + CD8T and CD38 + PD-1 + CD8T; and S5, performing a classification task by adopting TabPFNClassifier, performing training from features selected from the training data set, then evaluating the performance of the model, performing model training by utilizing detection data, and performing evaluation to construct a lupus nephritis prediction model with high accuracy.

The compositions comprise at least two ingredients selected from the group consisting of fish oil, L-arginine, vitamin E, vitamin C, vitamin B3, vitamin B5, vitamin B6, vitamin B1, vitamin B2, folic acid, biotin, vitamin B12, and are formulated for the prevention and / or treatment of a disease or condition associated with muscle decline in a subject in need thereof. Preferably, the subject in need is an individual at risk of or having renal failure, renal dysfunction or / and nephropathy, such as chronic nephropathy, protein energy consumption, end-stage nephropathy, renal failure due to hospitalization in an intensive care unit, acute kidney injury, and the muscle decline is selected from the group consisting of muscle depletion, muscle loss due to renal failure or dysfunction, muscle decline associated with chronic kidney disease, muscle loss due to hospitalization in intensive care units during renal failure, metabolic acidosis during chronic kidney disease, protein energy depletion, or a combination thereof. The method enables the prevention and / or treatment of at least one outcome of a disease or condition associated with muscle decline in a subject at risk of or having renal failure, renal dysfunction or / and kidney disease. The composition and the method can be used to improve the level of at least one amino acid.

The invention discloses application of oligopeptide in preparation of a medicine for treating and / or preventing diabetic nephropathy. The oligopeptides comprise oligopeptides with the amino acid sequence of SEQ ID NO: 1: LNLYP and derivative sequences or conservative substitution variants of the oligopeptides. The oligopeptide can significantly improve renal function indexes of mice with diabetic nephropathy, such as UACR, serum creatinine, urea nitrogen and the like, enhance podocyte barrier integrity and inhibit accumulation of advanced glycosylation end products AGEs in kidney tissues, and provides a basis for development of novel drugs for treating diabetic nephropathy.

The invention relates to a traditional Chinese medicine composition for treating spleen-kidney qi deficiency and stasis toxin obstruction type diabetic nephropathy, which can effectively solve the medication problem for treating spleen-kidney qi deficiency and stasis toxin obstruction type diabetic nephropathy. The traditional Chinese medicine composition is prepared from, by weight, 37-33 g of astragalus membranaceus, 27-33 g of centella asiatica, 18-22 g of ligusticum wallichii, 18-22 g of winged euonymus twig, 18-22 g of salvia miltiorrhiza and 14-16 g of prepared rehmannia root. The traditional Chinese medicine composition is prepared by removing impurities from the raw materials, washing, airing, smashing and evenly mixing. The components are simple, scientific and reasonable, are compatible according to the main and secondary relationship of monarch, minister, assistant and guide, are mutually correlated and compatible in function to play a role, and are combined to play the roles of clearing heat and promoting diuresis, detoxifying and activating blood, reinforcing qi and nourishing yin, and tonifying kidney and replenishing essence, so that the traditional Chinese medicine is effectively used for preparing the medicine for treating spleen-kidney qi deficiency and blood stasis toxin blocking type diabetic nephropathy, and is good in curative effect and free of toxic and side effects. The traditional Chinese medicine composition is a great innovation of medicines for treating spleen and kidney qi deficiency and stasis toxin blocking collateral type diabetic nephropathy, and has remarkable social and economic benefits.

Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.

The invention provides a diabetic nephropathy early warning method, system, equipment and medium, and relates to the technical field of medical data analysis and prediction.The method comprises the steps that multiple urine samples of a user are collected, target urine protein detection is conducted, and multiple urine protein concentrations are obtained; each urine protein concentration is combined with a normal urine protein concentration set to be input into an abnormal data recognition tree, the number of layers of multiple recognition nodes is obtained, and the detection confidence coefficient is obtained through calculation; configuring an abnormal proportion according to the detection confidence coefficient, inputting a plurality of urine protein concentration combination normal urine protein concentration sets into an abnormal data identification tree, deleting urine protein concentrations divided into abnormal data in the abnormal proportion before, and obtaining screened urine protein concentrations; according to the screened urine protein concentration, an auxiliary early warning coefficient is obtained through calculation, and early warning is carried out. The technical problem of low early warning accuracy of diabetic nephropathy in the prior art is solved.

The invention discloses a biomarker for nephrotic syndrome, an analysis method and a kit, which can be effectively used for diagnosis of nephrotic syndrome and have high sensitivity and accurate and reliable results. The biomarker for nephrotic syndrome comprises the mRNA, the protein and the enzymatic activity level of the following substances: lactate dehydrogenase B.

The invention relates to a flavonoid active fraction of an Abelmoschi corolla, a preparation method and an application thereof, and belongs to the field of traditional Chinese pharmaceutics. A high-purity Abelmoschi corolla flavonoid active fraction is prepared, which is found to have better therapeutic activity for kidney disease, and especially have a significant therapeutic effect for diabetic kidney disease and lupus nephritis, or contrast-induced kidney injury and eye diseases. Meanwhile, the Abelmoschi corolla flavonoid active fraction described in the invention also has good safety.

The present invention belongs to the field of probiotic fermentation technology, and specifically relates to a fermented product of Bifidobacterium longum subsp. infantis, and a preparation method thereof, and applications thereof in improving testosterone levels and fertilization rates, improving chronic kidney disease, and combating fatigue. The Bifidobacterium longum subsp. infantis NKU FB3-14 composition of the present invention and a probiotic fermented product prepared using the Bifidobacterium longum subsp. infantis NKU FB3-14 composition as a raw material have bioactive substances that are different from the raw materials, thereby achieving the effects of improving testosterone levels and fertilization rates, improving chronic kidney disease, and combating fatigue.

The invention discloses a traditional Chinese medicine extract composition for treating diabetic complications and a preparation method thereof, and belongs to the technical field of medicines. The traditional Chinese medicine extract composition is mainly prepared from the following raw material extracts: raw radix astragali, rhizoma anemarrhenae, rhizoma atractylodis, cortex phellodendri, radix trichosanthis, fructus corni, radix puerariae and ginseng leaves. The traditional Chinese medicine composition is used for treating diabetes mellitus and various complications thereof, including diabetes mellitus complicated with coronary heart disease, diabetes mellitus complicated with hypertension, diabetes mellitus complicated with cerebrovascular lesion, diabetic nephropathy, diabetic fundus lesion, diabetic peripheral neuropathy and the like, and has the advantages of remarkable clinical curative effect, no obvious side effect, low price, good comprehensive therapeutic property and the like.

The invention belongs to the technical field of biological medicines, and particularly relates to application of poecilobdella manillensis in preparation of a medicine for treating renal injury. The invention provides a new application of poecilobdella manillensis in preparation of a medicine for treating renal injury, serum biochemical index detection proves that the poecilobdella manillensis can effectively reduce serum creatinine and blood urea nitrogen levels, increase serum albumin and total protein content, remarkably improve glomerular filtration function and protein metabolism function, and improve renal function. And the improvement degree of the traditional Chinese medicine composition is superior to that of a traditional Chinese medicine contrast. Although the curative effect is slightly poorer than that of a chemical drug group, the safety advantage is remarkable. The poecilobdella manillensis can comprehensively regulate renal function metabolism indexes, relieve kidney injury and avoid common side effects of chemical drugs, provides a new choice for clinical treatment of kidney injury, and is especially suitable for chronic kidney disease patients needing long-term treatment.

The present invention discloses a culture medium, a fermentation method and an application of Streptomyces for producing pieridian glycosides. Through this fermentation method, the Streptomyces can produce abundant pieridian glycosides, and its effective part contains more than 8 types of pieridian glycosides at the same time, and the content of the four types of pieridian glycosides, namely compound 4, compound 5, compound 6 and compound 8, is greater than 5%. The extract obtained by the strain through this fermentation method and its effective part can be used to prepare drug lead compounds for treating renal cancer, organ fibrosis, acute kidney injury and chronic kidney disease, and can provide drug source guarantee for China's marine drug research and development.

The invention relates to the technical field of microorganisms, in particular to compound probiotics capable of degrading indole and preventing or relieving nephropathy and application of the compound probiotics. The compound probiotics comprise bifidobacterium animalis subsp. Lactis YYS-J9 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) NO.28185 and bifidobacterium longum subsp. Longum YYS-BSM8 with the preservation number of CGMCC NO.28611. The invention further discloses a preparation method of the compound probiotics. Compared with the use of a single YYS-J9 strain or YYS-BSM8 strain, the two strains have synergistic effects after being compounded, the viable count is remarkably increased after mixed culture, the inhibition effect on pathogenic enterobacteria and the adhesion to intestinal cells are remarkably enhanced, the degradation capacity on indole and oxalic acid is higher, the proliferation and phagocytic activity of macrophages is remarkably improved, and the application range of the YYS-J9 strain and the YYS-BSM8 strain is widened. And when being applied to food, health-care products or medicines, the exopolysaccharide can be used for effectively preventing or improving nephropathy and kidney stone, regulating intestinal health and improving intestinal immunity.

The invention relates to the technical field of medical artificial intelligence and chronic kidney disease management crossing, in particular to a nonlinear algorithm system for precise chronic disease management of chronic kidney diseases. Through deep coupling of algorithms and in combination with two exclusive quantification formulas, transformation of CKD chronic disease management from standardized follow-up visit to precise and dynamic algorithm driving is realized, and the core pain points of large staging evaluation deviation, progress pre-judgment lag, poor intervention scheme adaptability, follow-up visit strategy homogenization and the like in traditional CKD management are solved. The method provides full-cycle decision support for nephrology doctors in the three-A hospital, customizes an individualized chronic disease management path for CKD patients, is suitable for CKD 1-5 period full-staging patients, and can be widely applied to CKD special management scenes of chronic disease diagnosis and treatment centers in the nephrology department of the three-A hospital, chronic disease management outpatient clinics in special nephropathy hospitals and high-end health management institutions.

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

The invention discloses a method and system for predicting membranous nephropathy based on machine learning, and relates to the technical field of medical diagnosis and treatment, and the method comprises the steps: collecting multi-source heterogeneous data of a patient; preprocessing the multi-source heterogeneous data, constructing a mapping relation between the traditional Chinese medicine syndrome type and the molecular biomarker, and generating a traditional Chinese and western medicine fusion feature matrix; screening a feature subset related to membranous nephropathy prediction from the traditional Chinese and western medicine fusion feature matrix; constructing a membranous nephropathy multi-level prediction framework according to the feature subset, and training each prediction model in the framework; and applying the trained and optimized membranous nephropathy multi-level prediction framework to the feature subset data of the new patient to generate a membranous nephropathy multi-dimensional prediction result. By establishing the Chinese and western medicine feature mapping relation, deep fusion of traditional Chinese medicine diagnosis and modern medical indexes is realized, and comprehensiveness and accuracy of disease diagnosis are improved.

The invention provides a method and device for predicting diabetic nephropathy, electronic equipment and a storage medium. The method comprises the following steps: acquiring questionnaire data of a target diabetic patient, and a first fundus image and a second fundus image of the same type; constructing a target Bayesian network according to the questionnaire data; based on the target Bayesian network, calculating joint probability distribution of the target diabetic patient concurrent diabetic nephropathy to obtain a first probability value; performing difference feature extraction on the first fundus image and the second fundus image to obtain target difference feature data; performing concurrent diabetic nephropathy probability prediction on the target difference feature data to obtain a second probability value; and according to the first probability value and the second probability value, determining a target probability of complicating diabetic nephropathy of the target diabetic patient. The invention aims to construct a simple, economic and low-trauma early screening system for diabetic nephropathy.

The invention discloses a diabetic nephropathy patient retinopathy image classification method based on artificial intelligence, and relates to the technical field of medical images, and the method comprises the steps: collecting a retina image, carrying out the denoising and contrast adjustment, and generating a standardized image; carrying out feature constraint by utilizing a generative adversarial network guided by medical priori knowledge in combination with microaneurysm morphology and bleeding area texture features, generating a retina image with enhanced pathological features, and constructing an amplification training data set; training a deep convolutional neural network based on the data set, identifying microaneurysm and bleeding lesion by using a multi-scale feature extraction layer, and outputting a preliminary classification result; and a reinforcement learning environment is constructed in combination with clinician feedback, and a classification decision threshold is dynamically adjusted to optimize lesion grading parameters. According to the method, cross-modal correlation analysis is adopted, retinopathy features and biochemical time sequence data are fused, and the accurate classification capacity of diabetic retinopathy images is improved.

The present disclosure relates to flavor compositions and pet food products for preventing and / or treating chronic kidney disease (CKD) and / or urinary tract disease in an animal. In certain embodiments, the flavor compositions and pet food products have enhanced palatability.

The invention relates to application of targeted intervention FBP2mRNA in preparation of a medicine for preventing and treating diabetic nephropathy, and belongs to the technical field of biomedicine. The invention provides an application of FBP2mRNA as a therapeutic target in preparation of a medicine for preventing and treating diabetic nephropathy. The NCBI (National Center of Biotechnology Information) login number of the FBP2mRNA is NM003837.4. The invention also provides an application of the shRNA for specifically interfering with the expression of the FBP2mRNA in the preparation of a medicine for preventing and treating diabetic nephropathy, wherein the nucleotide sequence of the shRNA is shown as SEQ ID NO. 1. It is found for the first time that targeted inhibition of the expression level of FBP2mRNA can effectively reduce the lipid level in mouse glomerular podocytes, reduce the expression level of lipid synthesis related genes and reduce the activity of lipid synthesis protein, and then the effect of treating diabetic nephropathy is achieved, so that FBP2mRNA can be used as a drug treatment target, and the treatment effect of diabetic nephropathy is improved. The application is applied to research, development and preparation of diabetic nephropathy prevention and treatment medicines.